GLP-1 Drugs: The Complete Guide (2026)

← Peptides for Longevity: the evidence map

Generations, the patent cliff, the $15 generics, the pipeline, and every benefit beyond weight loss.

Longevity Notes · evidence-graded, source-cited · educational, not medical advice · current to mid-2026

The GLP-1 class is the most consequential drug story in modern medicine — a peptide that began as a diabetes treatment and now reshapes how we treat obesity, heart disease, kidney disease, liver disease, and possibly aging itself. This is the complete map: where these drugs came from, where they’re going, who owns them, why they’re about to get far cheaper, and everything they do besides weight loss — including the trials that failed.

What a GLP-1 actually is

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. It tells the pancreas to release insulin (only when glucose is high), suppresses glucagon, slows stomach emptying, and acts on appetite centres in the brain to make you feel full. The catch: natural GLP-1 is destroyed within ~2 minutes by the enzyme DPP-4. Every drug in this class is an engineered molecule that resists that breakdown — letting one injection (or pill) work for a day, a week, or longer. Crucially, receptors for these hormones sit not only in the gut and pancreas but in the heart, kidney, liver, blood vessels and brain — which is why the benefits reach far beyond weight.

The four generations

The class has evolved in four waves, each a leap in duration, potency, or the number of hormone targets.

Gen 1 — short-acting, exendin-based (mid-2000s)

Built from exendin-4, a peptide in Gila-monster venom that resists DPP-4. Exenatide (Byetta, twice-daily; Bydureon, weekly) and lixisenatide. Modest weight loss, frequent dosing.

Gen 2 — long-acting human analogs (2010s)

Liraglutide (Victoza/Saxenda, daily; ~5–8%) — now off-patent with generics live. Dulaglutide (Trulicity, weekly). Semaglutide — the blockbuster: Ozempic (diabetes), Wegovy (obesity), Rybelsus (the first oral GLP-1); ~15% weight loss; the world’s #2 best-selling medicine (~$26 bn in 2024, growing ~40%/yr).

Gen 3 — multi-receptor agonists (2022→)

Tirzepatide (Mounjaro/Zepbound) — the first dual GIP + GLP-1 “twincretin”, ~20–23%. CagriSema (semaglutide + the amylin analog cagrilintide, ~22.7%). Survodutide and mazdutide — GLP-1 + glucagon duals.

Gen 4 — triple agonists, oral small molecules, and beyond (2025→, arriving now)

Retatrutide — first-in-class triple agonist (GIP + GLP-1 + glucagon), up to ~25–30%. Orforglipron — a non-peptide oral small molecule (no injection, no food/water timing), now approved and marketed as Foundayo, ~12–15%. Plus amycretin (GLP-1 + amylin) and Amgen’s monthly-dosed MariTide.

The patent cliff, the price revolution, and the GLP-1 economy

Semaglutide’s Indian patent expired on March 20, 2026.¹³ Within 48 hours 15+ generics launched; 40–50+ brands are expected. Novo’s branded Ozempic/Wegovy in India ran ₹10,000–16,000/month (~$120–190); generics dropped to as low as ₹1,250–1,800/month (~$15–22) — up to 80–90% cheaper.¹⁴ The companies: Sun Pharma, Dr Reddy’s, Zydus, Lupin, Cipla, Natco, Alkem, Glenmark, Biocon. Every generic contains the same molecule; what differs is the delivery device, quality control, and price.

When each market opens

Patents fall market by market, not globally — so cheap generics reach high-obesity emerging markets roughly 5–7 years before the US/EU. Nearer-term US/EU relief comes from competition, the cheaper oral (orforglipron/Foundayo), and political price pressure.

How this shapes the next generations

Cheap generic semaglutide is a forcing function: once “good-enough” weight loss costs ~$15/month, Novo and Lilly can only justify premium pricing with better drugs — exactly why the pipeline is racing to triple agonists, amylin combos, and convenient orals. Generics commoditise the first wave; the innovators retreat to the frontier. Orforglipron’s low manufacturing cost is Lilly’s deliberate hedge against cheap injectable generics.

Who wins, who loses

Winners: Indian generic & CDMO/peptide-API makers; patients (mass access); telehealth/e-pharmacy; gyms & fitness; apparel; travel and live experiences. Losers / pressured: packaged food, snacks, soft drinks, confectionery; fast food & casual dining; bars & alcohol; cinema/theme-park food concessions; and Novo’s margins.

The ripple economy

GLP-1s are becoming a macro force. ~12% of US adults have used one; US obesity fell ~40% → 37% (2022→2025).¹² The documented spillovers go well past the scale.

Other spillovers: ~15% more users report a positive body image (PwC), redirecting spend toward gyms, travel, concerts and live sport; early signals of lower alcohol, nicotine and even gambling/opioid cravings (the reward-pathway effect); large long-term healthcare savings from less obesity-driven disease, set against high near-term drug spend (who pays is the central policy fight); GLP-1 revenue now exceeds the combined revenue of the leading AI labs, and Novo alone has represented ~10% of Denmark’s GDP. As generics reach the middle- and lower-income majority in high-obesity countries, this stops being an affluent-Western phenomenon and becomes a global population-health intervention.

How investors frame the theme (not advice): long the innovators holding the frontier pipeline and the generic/CDMO supply chain; watch the fitness/experiences beneficiaries; treat packaged-food/restaurant/alcohol exposure as a structural headwind — while remembering the staples hit is still small versus inflation and easy to over-extrapolate.

Beyond weight loss — every benefit, graded

The benefits span nearly every major organ system. Here’s the map, by organ and evidence strength (A = multiple RCTs / approved; B = limited RCTs; C = promising but unproven):

ACardiovascular. SELECT (17,604 adults, overweight/obese + CVD, no diabetes): semaglutide cut major cardiovascular events ~20%¹ — making it the first weight-loss drug FDA-approved (2024) to reduce CV risk, with benefit partly independent of weight lost. It also reduced all-cause mortality. Heart failure (HFpEF): STEP-HFpEF (semaglutide)³ and SUMMIT (tirzepatide)⁴ both positive.

AKidney. FLOW (semaglutide, CKD + type 2 diabetes)² was stopped early for efficacy — slowing kidney decline and reducing kidney/CV death.

A/BLiver (MASH). ESSENCE (semaglutide)⁶ improved metabolic-dysfunction-associated steatohepatitis; survodutide and retatrutide show striking liver-fat reductions (retatrutide ~86% in Phase 2).

ASleep apnea. SURMOUNT-OSA (tirzepatide)⁵ → Zepbound approved for OSA (Dec 2024), the first drug for the condition.

BPeripheral artery disease. STRIDE (semaglutide)⁷ improved walking distance and symptoms.

BOsteoarthritis. Knee OA + obesity: semaglutide (STEP-9) and retatrutide (TRIUMPH-4) reduced pain and improved function.¹⁰

CAddiction / reward. Large observational datasets (e.g. 600,000+ US veterans) link GLP-1 use to lower alcohol and substance-use-disorder risk (~14% lower in one analysis).¹⁰ Dedicated trials are underway — plausible, not yet proven.

CDementia / cognition — with a major caveat. Observational data repeatedly link GLP-1 use to lower dementia risk, but the dedicated trials failed: EVOKE and EVOKE+⁹ (3,808 people with early Alzheimer’s, the largest GLP-1 trials ever in a neurodegenerative disease) showed no slowing of Alzheimer’s progression (late 2025), despite improvements in inflammatory and AD biomarkers. The honest read: semaglutide does not treat established Alzheimer’s; whether it might prevent dementia if started before symptoms is a separate, open question.

The breadth comes from more than weight loss: GLP-1s appear to reduce systemic and vascular inflammation, modulate neuroinflammation, cut platelet aggregation and atherosclerosis, protect vascular integrity, and lower oxidative stress.

Safety and the honest caveats

GI (nausea, vomiting, diarrhea, constipation) is the common one — usually dose-dependent and improving over weeks; ~20% discontinued in trials for side effects. Muscle loss: rapid weight loss takes lean mass too — resistance training + adequate protein matter, especially in older people. Rebound: weight tends to return after stopping; these treat a chronic condition. Rare but serious: pancreatitis, gallbladder disease; a thyroid-cancer (MTC) boxed warning means they’re avoided with a personal/family history of MTC or MEN2. Not for type 1 diabetes, DKA, or a history of pancreatitis or those thyroid cancers. “Ozempic face” (facial volume loss) is cosmetic. And as with all peptides, gray-market/compounded “semaglutide” is largely unauthorized now that shortages have resolved — source and dose accuracy matter.

Is this a “longevity” drug?

Not proven, but the most credible candidate the class has produced. For: it reduces cardiovascular events, kidney decline and all-cause mortality in large trials, with effects partly independent of weight loss — consistent with dampening the metabolic and inflammatory drivers of aging. Against: there’s no lifespan/healthspan trial; unmanaged muscle loss cuts the wrong way; and the one neurodegeneration trial failed. The honest position: a powerful cardiometabolic therapy with the strongest mortality evidence of any peptide — but “longevity drug” is, for now, an extrapolation, not a finding.

References

1. SELECT — Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 2023.
2. FLOW — Effects of semaglutide on chronic kidney disease in type 2 diabetes. NEJM, 2024.
3. STEP-HFpEF — Semaglutide in heart failure with preserved ejection fraction and obesity. NEJM, 2023.
4. SUMMIT — Tirzepatide in HFpEF and obesity. NEJM, 2025.
5. SURMOUNT-OSA — Tirzepatide for obstructive sleep apnea. NEJM, 2024.
6. ESSENCE — Semaglutide in metabolic-dysfunction-associated steatohepatitis (MASH). NEJM, 2025.
7. STRIDE — Semaglutide in peripheral artery disease. The Lancet, 2025.
8. Retatrutide TRIUMPH-1 & TRIUMPH-4 — Phase 3 topline results, Eli Lilly, 2025–2026. prnewswire.com
9. EVOKE & EVOKE+ — Semaglutide in early Alzheimer’s disease (negative), presented CTAD 2025. science.org
10. The expanding benefits of GLP-1 medicines (review). PMC, 2025. pmc.ncbi.nlm.nih.gov
11. Hristakeva S, Liaukonytė J, Feler L. The No-Hunger Games: how GLP-1 medication adoption is changing consumer food demand. Journal of Marketing Research, 2025. doi:10.1177/00222437251412834. Cornell Chronicle
12. Ozempic is changing the consumer economy. Washington Post, 2025. washingtonpost.com
13. Novo Nordisk and India’s generic semaglutide launch. CNBC, Mar 2026. cnbc.com
14. Off-patent semaglutide in 2026. IQVIA, 2025. iqvia.com
15. Looming GLP-1 drug patent expirations. Chemical & Engineering News, Dec 2025. cen.acs.org
16. Health benefits of semaglutide beyond weight loss. Mayo Clinic Press, 2026. mcpress.mayoclinic.org

Educational only — not medical advice; anything prescription or gray-market should go through a physician. References above are the primary trials and data sources; per-claim inline citation markers are added in the final editorial pass.